恩杂鲁胺与阿比特龙在转移性去势抵抗性前列腺癌一线及二线治疗中的真实世界总生存比较
Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.
作者信息
Horváth András, Blasszauer Celia, Komka Ida, Reibl Dániel, Hadaschik Boris, Fazekas Tamás, Rajwa Pawel, Soós Àron, Valikovics Anikó, Nyirády Péter, Szarvas Tibor
机构信息
Department of Urology, Semmelweis University, Budapest, Hungary.
MedicalScan Ltd., Budapest, Hungary.
出版信息
Prostate. 2025 Sep;85(12):1151-1154. doi: 10.1002/pros.24923. Epub 2025 Jun 8.
BACKGROUND
While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.
METHODS
A large, country-wide health insurance database (2013-2023) was assessed for the OS comparison between abiraterone and enzalutamide.
RESULTS
Overall, 3497 patients were identified with first- (n = 2215) or second-line (n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide-treated patients had longer OS both in the first- (HR:0.84; 95%CI:0.74-0.96; p = 0.008) and the second-line setting (HR:0.88; 95%CI:0.78-0.99; p = 0.043), respectively.
CONCLUSIONS
This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.
背景
虽然阿比特龙和恩杂鲁胺的适应症有重叠，但尚无临床试验比较二者在转移性去势抵抗性前列腺癌（mCRPC）中的总生存期（OS）。
方法
评估一个大型的全国性医疗保险数据库（2013 - 2023年），以比较阿比特龙和恩杂鲁胺的总生存期。
结果
总体而言，共识别出3497例接受一线（n = 2215）或二线（n = 1282）阿比特龙或恩杂鲁胺治疗的患者（仅66例序贯接受了两种药物治疗）。恩杂鲁胺治疗的患者在一线治疗（HR：0.84；95%CI：0.74 - 0.96；p = 0.008）和二线治疗（HR：0.88；95%CI：0.78 - 0.99；p = 0.043）中总生存期均更长。
结论
这项基于医疗保险登记处的研究表明，在真实世界的mCRPC环境中，恩杂鲁胺在总生存期方面优于阿比特龙。
Zotero 插件